Status:
COMPLETED
Tamoxifen Study
Lead Sponsor:
NSABP Foundation Inc
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cardiovascular Diseases
Coronary Disease
Eligibility:
FEMALE
35-75 years
Phase:
PHASE3
Brief Summary
To assess the impact of tamoxifen on development of breast cancer, coronary heart disease, and bone fractures. The National Cancer Institute initiated the prevention trial under its National Surgical ...
Detailed Description
BACKGROUND: Tamoxifen is nominally called an 'anti-estrogen' although it has some estrogen-agonist activities and tends to increase plasma endogenous estrogen levels. Several studies have confirmed t...
Eligibility Criteria
Women over the age of 35 with a 5-year predicted breast cancer risk of at least 1.66 percent or a history of lobular breast carcinoma in situ, life expectancy of 10 years or more, breast examination and mammogram without evidence of cancer, no hormonal therapy within three months prior to randomization, and no history of deep venous thrombosis or pulmonary embolism. .
Key Trial Info
Start Date :
May 1 1992
Trial Type :
INTERVENTIONAL
End Date :
November 1 1995
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000529
Start Date
May 1 1992
End Date
November 1 1995
Last Update
November 2 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.